Haiying Cheng

3.6k total citations · 2 hit papers
125 papers, 2.4k citations indexed

About

Haiying Cheng is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Haiying Cheng has authored 125 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Pulmonary and Respiratory Medicine, 72 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Haiying Cheng's work include Lung Cancer Treatments and Mutations (61 papers), Cancer Immunotherapy and Biomarkers (29 papers) and Lung Cancer Research Studies (24 papers). Haiying Cheng is often cited by papers focused on Lung Cancer Treatments and Mutations (61 papers), Cancer Immunotherapy and Biomarkers (29 papers) and Lung Cancer Research Studies (24 papers). Haiying Cheng collaborates with scholars based in United States, China and Taiwan. Haiying Cheng's co-authors include Román Pérez-Soler, So Yeon Kim, Mariam Alexander, Balázs Halmos, Alain Borczuk, Bilal Piperdi, Xuewen Liu, Xingxing Zang, Mahesh Mansukhani and Murali Janakiram and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Haiying Cheng

119 papers receiving 2.3k citations

Hit Papers

Update 2020: Management of Non-Small Cell Lung Cancer 2020 2026 2022 2024 2020 2025 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Update 2020: Management of Non-Small Cell Lung Cancer
    2020 437 citations Mariam Alexander, Haiying Cheng et al. profile →
  2. Update 2025: Management of Non‑Small-Cell Lung Cancer
    2025 17 citations Haiying Cheng et al. profile →

Peers

Haiying Cheng
Francesco Passiglia Italy
Amanda J. Redig United States
Enric Carcereny Spain
Alexander J. Chou United States
J.C. Soria France
Antonio Calles Spain
Maria Giovanna Dal Bello Italy
Ingeborg Tinhofer Germany
Isabell Witzel Germany
Pol Specenier Belgium
Francesco Passiglia Italy
Haiying Cheng
Citations per year, relative to Haiying Cheng Haiying Cheng (= 1×) peers Francesco Passiglia

Countries citing papers authored by Haiying Cheng

Since Specialization
Citations

This map shows the geographic impact of Haiying Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiying Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiying Cheng more than expected).

Fields of papers citing papers by Haiying Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiying Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiying Cheng. The network helps show where Haiying Cheng may publish in the future.

Co-authorship network of co-authors of Haiying Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Haiying Cheng. A scholar is included among the top collaborators of Haiying Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiying Cheng. Haiying Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ohri, Nitin, William Bodner, Rafi Kabarriti, et al.. (2025). Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT). International Journal of Radiation Oncology*Biology*Physics. 122(2). 365–373. 1 indexed citations
2.
3.
Postovalova, Ekaterina, Meng Wang, Matthew Lee, et al.. (2025). Transcriptomic Profiling and Tumor Microenvironment Classification Reveal Unique and Dynamic Immune Biology in HIV-Associated Kaposi Sarcoma. Cells. 14(2). 134–134. 1 indexed citations
4.
Ma, Xinglong, Yifan Wang, Shen Liang, et al.. (2024). Design and performance analysis on a breathing-type instant heat recovery module for fresh air ventilation. Energy and Buildings. 310. 114107–114107. 3 indexed citations
5.
Kozono, David, Xing Hua, Michael C. Wu, et al.. (2024). Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Journal of Thoracic Oncology. 19(12). 1618–1629. 3 indexed citations
6.
Cheng, Haiying, et al.. (2023). Tunable photoluminescence of Ba2GdF7: Tb3+, Eu3+ nanoparticles based on energy transfer. Journal of Luminescence. 261. 119914–119914. 7 indexed citations
7.
Deng, Lei, Christopher Su, Xingxing Zang, et al.. (2023). Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways. Cancers. 15(13). 3372–3372. 11 indexed citations
8.
Ohri, Nitin, Shruti Jolly, Benjamin T. Cooper, et al.. (2023). Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT). Journal of Clinical Oncology. 42(5). 562–570. 25 indexed citations
9.
Andraos, T.Y., Balázs Halmos, Haiying Cheng, et al.. (2022). Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy. Clinical Lung Cancer. 23(4). 291–299. 5 indexed citations
10.
Chaudhary, Kunal, Connor J. Kinslow, Haiying Cheng, et al.. (2022). Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Scientific Reports. 12(1). 10140–10140. 10 indexed citations
11.
12.
Okabe, Rachel, Alexandra Schurer, Meng Tong, et al.. (2022). Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clinical Cancer Research. 29(5). 943–956. 1 indexed citations
13.
14.
Ohri, Nitin, Balázs Halmos, William Bodner, et al.. (2020). Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis. Practical Radiation Oncology. 11(2). e172–e179. 13 indexed citations
15.
Deng, Qinfang, Qiyu Fang, Hui Sun, et al.. (2020). Detection of plasmaEGFRmutations for personalized treatment of lung cancer patients without pathologic diagnosis. Cancer Medicine. 9(6). 2085–2095. 12 indexed citations
16.
Ohri, Nitin, Balázs Halmos, William Bodner, et al.. (2019). Daily Step Counts Predict Outcomes for Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics. 105(1). E524–E525. 1 indexed citations
17.
Herrera, Diego Adrianzen, et al.. (2018). Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expert Opinion on Pharmacotherapy. 20(1). 95–102. 56 indexed citations
18.
Wang, Rui, et al.. (2017). Precision drug development in ROS1-positive lung cancer. Expert Review of Precision Medicine and Drug Development. 2(2). 99–107.
19.
Borczuk, Alain, et al.. (2017). P2.01-056 Distinct PD-L1 Expression in Different Components of Pulmonary Sarcomatoid Carcinoma and Its Association with MET Mutation. Journal of Thoracic Oncology. 12(1). S819–S820. 2 indexed citations
20.
Pérez-Soler, Román, et al.. (2016). Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer. Current Treatment Options in Oncology. 17(3). 13–13. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Passiglia Breakdown of academic impact, for papers by Amanda J. Redig Breakdown of academic impact, for papers by Enric Carcereny Breakdown of academic impact, for papers by Alexander J. Chou Breakdown of academic impact, for papers by J.C. Soria Breakdown of academic impact, for papers by Antonio Calles Breakdown of academic impact, for papers by Maria Giovanna Dal Bello Breakdown of academic impact, for papers by Ingeborg Tinhofer Breakdown of academic impact, for papers by Isabell Witzel Breakdown of academic impact, for papers by Pol Specenier
Rankless by CCL
2026